Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 53

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 53
---
 our research and development facilities.

We
also have a pipeline of therapeutic devices for both veterinary and human clinical applications. Some such devices may be regulated by
the FDA or other equivalent regulatory agencies, including but not limited to the Center for Veterinary Medicine (“CVM”).
We anticipate growing our product pipeline through the acquisition or in-licensing of additional proprietary products from human medical
device companies specifically for use in pets. In addition to commercializing our own products in strategic market sectors and in view
of the Company’s vast proprietary product pipeline, the Company may establish strategic out-licensing partnerships to provide secondary
revenues.

26

RESULTS
OF OPERATIONS

The
following discussion should be read in conjunction with our 2025 10-K Report and the condensed consolidated financial statements and
related notes in Item 1, Financial Statements appearing elsewhere in this Quarterly Report on Form 10-Q (“10-Q Report”).
The following discussion may contain forward-looking statements, and our actual results may differ
materially from the results suggested by these forward-looking statements. Factors that might cause such differences include, but are
not limited to, those discussed in Part I, Item 1A of our 2025 10-K Report under the heading “Risk Factors,” as updated and
supplemented by risks described in other SEC filings. The Company assumes no obligation to revise or update any forward-looking statements
for any reason, except as required by law.

We
are a smaller reporting company and have incurred substantial losses in connection with our operations. We will need substantial capital
to pursue our current plans to commercialize our initial product, Spryng®.

RESULTS
OF OPERATIONS

    For
    the Three Months Ended 

    June
    30, 2025  
    June
    30, 2024 
  
    Revenues 
    $297,500  
    $123,751 

    Cost of Sales 
     110,774  
     12,994 

    Total Operating Expenses 
     2,031,043  
     2,155,189 

    Total Other Income (Expense) 
     (466,720) 
     (2,631)

    Net Loss 
    $(2,311,037) 
    $(2,047,063)

    Net loss per share - basic and diluted 
    $(0.09) 
    $(0.11)

For
The Three Months Ended June 30,